[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571308":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":38,"collaborators":42,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Diakonhjemmet Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who initiate or switch biological or targeted synthetic DMARD",null,"All patients initiate or switch biological or targeted synthetic DMARD",[13],"Drug: Biological or targeted synthetic DMARD",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Biological or targeted synthetic DMARD","All biological or targeted synthetic DMARDs that are available for treatment of patients with inflammatory joint diseases",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Ida K Haugen, MD PhD","CONTACT","+47 95859884","ida.k.haugen@gmail.com",[27],{"facility":5,"status":28,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"RECRUITING","Oslo","Norway","NO",{"type":33,"coordinates":34},"Point",[35,36],10.74609,59.91273,{"lat":36,"lon":35},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ida Kristin Haugen","MD PhD",[43],{"name":44,"class":6},"University of Oslo","100571308","pain-in-inflammatory-joint-diseases-100571308",false,"NCT06718569","Pain in Inflammatory Joint Diseases","Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management","Nor-Pain","Inclusion Criteria:\n\n* All patients who initiate or switch biological or targeted synthetic DMARDs\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":56,"type":57},350,"ESTIMATED","OBSERVATIONAL","Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.",[61,62,63,64,65,66],"Arthritis","Arthritis, Juvenile Idiopathic","Arthritis,Rheumatoid","Arthritis, Reactive","Arthritis, Psoriatic","Spondyloarthritis (SpA)","2026-04-07",{"date":69,"type":70},"2026-04-13","ACTUAL",{"date":72,"type":70},"2025-11-11",{"date":74,"type":57},"2027-11",{"name":5,"class":6},1]